07:00 , Jul 4, 2011 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Stand and deliver

Several market cap bands tracked by BioCentury did well last quarter, as investors rewarded late-stage data and transformative deals. The NYSE Arca Biotechnology Index and the BioCentury 100 each gained 7% in 2Q, while the...
07:00 , May 23, 2011 |  BC Week In Review  |  Clinical News

Calsed amrubicin: Phase III data

The open-label, international Phase III ACT-1 trial in 637 patients showed that IV amrubicin as second-line therapy missed the primary endpoint of significantly improving OS vs. topotecan (7.5 vs. 7.8 months, p=0.17). Amrubicin also missed...
07:00 , May 23, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $3.67 (14%) to $30.38 on Friday, while partner Biogen Idec Inc. (NASDAQ:BIIB) was up $0.39 to $97.11, after EMA's CHMP reversed a prior decision and recommended conditional approval...
00:41 , May 20, 2011 |  BC Extra  |  Clinical News

Amrubicin misses in lung cancer

Second-line treatment with amrubicin from Celgene Corp. (NASDAQ:CELG) missed the primary endpoint of significantly improving overall survival vs. topotecan in the Phase III ACT-1 trial to treat small cell lung cancer (SCLC), according to an...
07:00 , Oct 12, 2004 |  BC Extra  |  Clinical News

COM completes enrollment in fibrillation Phase III

Cardiome (TSE:COM; CRME) completed enrollment of 420 patients with atrial fibrillation in the Phase III ACT-1 trial of its RSD1235 antiarrhythmic. The primary endpoint is acute conversion to normal heart rhythm in recent-onset patients. The...